Related Information
Novoeight®
[Antihemophilic Factor (Recombinant)]
For US Health Care Professionals Only
![Novoeight® [Antihemophilic Factor (Recombinant)]](/content/dam/novonordisk/novoeightpro/global-images/logo-novoeight.png){kind=logo}
For US Health Care Professionals Only
This guide provides HCPs with an overview of NovoSecure™, a support program designed to assist your patients throughout the reimbursement process.
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery
Novoeight® (antihemophilic factor, recombinant) is an injectable medicine used to control and prevent bleeding in people with hemophilia A. Your healthcare provider may give you Novoeight when you have surgery
If you like the efficacy and fixed dosing of Novoeight (antihemophilic factor, recombinant), take a look at Esperoct® for your hemophilia A patients. With a longer half-life across age groups than standard half-life FVIII products, Esperoct® could be right for your patients.1,a,b
Please click here for Esperoct® Prescribing Information
Please click here for Novoeight® Prescribing Information
aA phase 1, open-label study evaluated the safety and pharmacokinetic properties of Esperoct® in 26 PTPs. Patients received a single dose of 25, 50, or 75 IU/kg of their previous SHL product (pdFVIII or rFVIII), followed by the same dose of Esperoct®. To allow for comparison, all results were adjusted to a 50 IU/kg dose of each product.1
bIn a phase 3 study of children (aged <12 years) a single-dose PK comparison was performed in 27 children between previous SHL products and Esperoct® at the same administered dose prior to the start of routine prophylaxis. Half-life comparison is based upon the estimated half-life derived from a population-based model. During the main phase, 68 children received prophylaxis at an average dose of approximately 65 IU/kg twice weekly for 26 weeks.2
References:
Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.
